Current and future advances in practice: aromatase inhibitor-induced arthralgia.
Current and future advances in practice: aromatase inhibitor-induced arthralgia. Rheumatol Adv Pract. 2024; 8(2):rkae024.
PMID: 38601139
Immune Checkpoint Inhibitors and Lupus Erythematosus.
Immune Checkpoint Inhibitors and Lupus Erythematosus. Pharmaceuticals (Basel). 2024 Feb 15; 17(2).
PMID: 38399467
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. Oncoimmunology. 2023; 12(1):2261264.
PMID: 38126033
JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul-Dec; 19(11):1385-1397.
PMID: 37596779
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 11; 46(11):1049-1071.
PMID: 37490213
Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis.
Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis. Respir Med. 2023 Oct; 217:107330.
PMID: 37385460
Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis.
Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis. RMD Open. 2023 06; 9(2).
PMID: 37355249
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 05 08; 28(5):440-448.
PMID: 36595378
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events.
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events. JAMA Oncol. 2023 05 01; 9(5):723-724.
PMID: 36892846
Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events.
Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events. J Cancer Educ. 2023 10; 38(5):1486-1492.
PMID: 37022615